BCL2 and diffuse large B-cell lymphoma: Among the 140 patients with DLBCL, aaIPI (P = 0.003) (Figure 3(a)), BAD (P = 0.048) (Figure 3(b)), BAX (P = 0.003) (Figure 3(c)), BCL-2 (P = 0.046) (Figure 3(d)), YWHAZ (P ≤ 0.001) (Figure 3(e)), primary site (P ≤ 0.001) (Figure 3(f)), age (P = 0.004) (Figure 3(g)), hyphemia (P = 0.002) (Figure 3(h)), ECOG PS (P = 0.016) (Figure 3(i)), systemic disease (P = 0.024) (Figure 3(j)), LDH (P = 0.001) (Figure 3(k)), and treatment mode (P ≤ 0.001) (Figure 3(l)) affected the OS.